Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT plus Bevacizumab in Advanced Non-squamous NSCLC
NCT07244926Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07244926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244926.